摘要
86例经病理证实的原发性肺癌以阿霉素联合化疗方案治疗。年龄中位数58岁,KPS>50,为不适于手术的Ⅲ、Ⅳ期或拒作手术的Ⅱ期NSCLC或Ⅱ期SCLC。40例SOLC用环磷酰胺、ADM和长春新醶(CAO)或以异环磷酰胺替代环磷酰胺(IAO).缓解率57.5％。IAO缓解率优于CAO,分别为78.6％和46.2％,内5例因化疗有效获手术切除,内3例手术发现化疗后期别提早,有1例标本内未发现癌细胞,说明阿霉素联合方案可成为SCLC的诱导治疗。另46例NSCLC用丝裂霉素ADM和顺铂(MAP),缓解率41.3％,均为PR,提示也有作为诱导治疗的可能,其疗效达目前NSCLC较好的化疗方案要求。86例用阿霉素联合方案,无1例出现心脏毒副反应,脱发副反应最多,为100％,白细胞下降也较多见,45.3％为Ⅱ°,31.4％为Ⅲ°,下降最低时间为化疗后平均13.4天(6—22天),平均19.6天恢复(14—26天)。
Eighty six cases of pathologically proved primary lung cancer were treated withadriamycin oombination chemotherapy. The median age was 58 and KPS>50. The pa-tients were in inoperable stage Ⅲ and Ⅳ NSCLC, stage Ⅱ NSCLC who refused opera-tion, and stage Ⅱ SCLC. 40 cases of SCLC treated with CAO (CTX, ADM, VCR) orwith IAO (CTX substituted by IFO) had an average remission rate of 57.5% (IAO78.6%, CAO 46.2%). 5/40 cases could be resected after chemotherapy, 3 among the 5with clinical stage became earlier and 1 surgical specimen showed no cancer cells.This indicates that adriamycin combination chemotherapy can be an induction therapyfor SCLC. 46 cases of NSCLC treated with MAP (MMC, ADM, DDP) had an all PRremission rate 41.3% indicating a possibility for induction therapy too. Not a caseshowed side effect of heart, but hair losing was 100%, decrease of white blood cellwas often (Ⅱ°45.3%, Ⅲ°31.4%) with the lowest level reached at 13.4 days afterchemotherapy and recovered at 19.6 days in average.
出处
《肿瘤》
CAS
CSCD
北大核心
1993年第1期7-9,共3页
Tumor
